Management of Complex Cardiovascular Conditions

Current Medication Assessment

The American Heart Association recommends optimizing current medications, including increasing telmisartan dose, for patients with HFpEF and hypertension 1, 2, 3
Telmisartan (40mg) is likely underdosed for a patient with average BP of 150/80 mmHg; current guidelines recommend adequate blood pressure control in HFpEF patients to improve filling pressures and promote regression of hypertrophy 1
Metformin (500mg) is appropriate as baseline therapy for DMT2 and can be safely continued alongside the other medications 3

The American College of Cardiology suggests that beta-blockers, ACE inhibitors, and ARBs are reasonable to control BP in HFpEF patients with hypertension 1
Increase telmisartan to 80mg daily to achieve better blood pressure control, as current BP of 150/80 exceeds recommended targets for patients with cardiovascular disease 1
Add a beta-blocker (preferably bisoprolol, carvedilol, or metoprolol succinate) which is reasonable for HFpEF patients with hypertension and would also help manage the moderate valvular regurgitation 2, 4

Consider adding a mineralocorticoid receptor antagonist (MRA) such as spironolactone, which may benefit patients with HFpEF, especially those with elevated natriuretic peptide levels 2, 3

The American College of Cardiology recommends regular echocardiographic monitoring (every 6-12 months) for patients with moderate valvular disease 2
Avoid non-dihydropyridine calcium channel blockers (diltiazem, verapamil) due to their negative inotropic effects which could worsen heart failure symptoms in the context of valvular disease 1, 5

Consider adding low-dose aspirin (75-160mg daily) for patients with a history of TIA and peripheral artery disease, if not contraindicated 3

Monitor blood pressure regularly, aiming for a target of <130/80 mmHg 1
Schedule regular echocardiographic follow-up (every 6-12 months) to assess valvular disease progression 2
Monitor renal function and electrolytes, particularly after medication adjustments 4
Assess for signs of fluid overload and adjust diuretic therapy as needed 6

Avoid hydralazine monotherapy as it may provoke myocardial ischemia, though hydralazine-isosorbide dinitrate combination could be considered if the patient becomes intolerant to ARB therapy 7
Avoid non-dihydropyridine calcium channel blockers (diltiazem, verapamil) which are contraindicated in heart failure 1, 8
Be cautious with high-dose diuretics which may worsen renal function; consider sequential nephron blockade if diuretic resistance develops 6
Monitor for potential drug interactions, particularly between the cardiovascular and diabetes medications 3